|Bid||4.61 x 301500|
|Ask||0.00 x 36100|
|Day's Range||4.5900 - 4.6600|
|52 Week Range||4.2100 - 7.1000|
|Beta (3Y Monthly)||0.75|
|PE Ratio (TTM)||9.63|
|Forward Dividend & Yield||0.30 (6.60%)|
|1y Target Est||N/A|
DALLAS, Feb. 12, 2019 /PRNewswire/ -- Santander Consumer USA ("SC") and Chrysler Capital are offering eligible1 customers who sign up for paperless statements as of April 1, 2019, the chance to win a $10,000 grand prize or one of five $500 prizes for each brand. When eligible1 Santander Consumer USA and Chrysler Capital customers enroll in e-statements at the appropriate website, they will be automatically entered into the sweepstakes. Eligible Santander Consumer USA and Chrysler Capital customers who already are enrolled in e-statements, also known as electronic or paperless statements, will be entered as well.
BOSTON , Feb. 12, 2019 /PRNewswire/ -- Santander Bank today announced that Robert Cerminaro has been promoted to Commercial Banking market director for New England. He is responsible for managing and growing ...
February 12, 2019 - Sanofi has appointed Ameet Nathwani, M.D. as Chief Digital Officer in addition to his current role of Executive Vice President, Chief Medical Officer. As Chief Digital Officer, Dr. Nathwani will be responsible for enhancing Sanofi's strategy to integrate digital technologies and medical science to ultimately improve patient outcomes.
Paris, February 7, 2019 Sanofi delivers 2018 business EPS growth of 5.1% at CER Q4 2018 Change Change at CER 2018 Change Change at CER IFRS net sales.
February 6, 2019 - At its meeting held on February 6, 2019, the Board of Directors duly noted the resignation of Mr. Mulliez and decided, after consultation of the Appointments and Governance Committee, to co-opt Christophe Babule as Director for the remainder of Christian Mulliez's term of office (expiring at the end of the Annual Shareholders' Meeting held in 2022 to approve the financial statements for the fiscal year ending December 31, 2021). The co-optation of Christophe Babule will be subject to ratification by the next Shareholders' Meeting of Sanofi, on April 30, 2019. On November 19, 2018 Christophe Babule has been appointed Executive Vice-President, Chief Financial Officer and member of L'Oréal's Executive Committee as of mid-February 2019.
February 6, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the first FDA approved therapy specifically indicated for the treatment of aTTP.
Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma Study evaluated the benefit.
February 4, 2019 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Praluent® (alirocumab), recommending a new indication as an adjunct to correction of other risk factors. Praluent should be used in addition to a maximally tolerated dose of statin or can be used alone in patients intolerant to or inappropriate for statin therapy. The CHMP opinion is based on data from ODYSSEY OUTCOMES, a Phase 3 cardiovascular outcomes trial that assessed the effect of Praluent in 18,924 patients who had an ACS between 1-12 months (median 2.6 months) before enrolling in the trial.
January 30, 2019 - Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT), more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC). This approval paves the way for the distribution of fexinidazole in endemic countries this year, with another submission planned in Uganda.
January 17, 2019 - The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of whether the overall benefits of Zynquista(TM)* (sotagliflozin) outweighed the risks to support approval. Sotagliflozin is an investigational oral dual SGLT1 and SGLT2 inhibitor under regulatory review as an adjunct to insulin for the treatment of adults with type 1 diabetes (T1D). While the FDA is not required to follow the committee's vote, the agency considers the committee's recommendations when making its decision, which is anticipated by March 22, 2019.
BOSTON, Jan. 14, 2019 /PRNewswire/ -- Santander Bank today announced that its Commercial Banking division has enhanced its capabilities to better serve the needs of specific industries and has named Emily Vaughan Alexanderson to lead its specialized banking group, serving clients in the non-profit, educational, professional services, and technology and life sciences industries. David Harnisch, Santander Bank's Head of Commercial Banking, said, "We continue to make significant investments to support our growing commercial business and deliver valuable ideas to help our clients prosper.
BOSTON , Jan. 14, 2019 /PRNewswire/ -- Santander Bank today announced that it has donated more than $2 million to 66 non-profit organizations that support low- and moderate-income (LMI) individuals, families ...
January 7, 2019 - Sanofi (EURONEXT: SAN, NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (REGN) have restructured their global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. The 2015 Agreement was scheduled to end in approximately mid-2020, and this revision provides for ongoing collaborative development of two clinical-stage bispecific antibody programs.
BOSTON, Dec. 20, 2018 /PRNewswire/ -- Santander Bank today announced the appointment of Colleen Canny as head of its Retail Network. Canny brings nearly 30 years of consumer banking and wealth management experience to Santander. Colleen is responsible for increasing colleague engagement and retention, deepening and growing customer relationships, and improving the customer experience to ensure the delivery of Santander's value proposition.
BOSTON , Dec. 20, 2018 /PRNewswire/ -- Santander Bank announced today it has raised its prime rate from 5.25% to 5.50%, effective December 19, 2018 . Santander Bank , N.A . is one of the country's largest ...
BOSTON, Dec. 19, 2018 /PRNewswire/ -- Santander Bank today announced the opening of its newest branch in Brooklyn in the Bedford-Stuyvesant neighborhood, located on 1298 Fulton Street. To commemorate the new location, Santander leaders joined community partners at a grand opening celebration and ribbon cutting on Friday, Dec. 14 to officially open the branch. Santander presented checks totaling $26,000 to three community organizations – Brooklyn Neighborhood Services, Bedford Stuyvesant Restoration Corporation and New York Crusaders.
December 19, 2018 - The European Commission has granted marketing authorization for Dengvaxia®, Sanofi's dengue vaccine. The marketing authorization follows the October 18, 2018, recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to approve use of the dengue vaccine in European endemic areas.
December 18, 2018 - Sanofi today announced that it will be transferring the listing of its American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market (Nasdaq) effective December 31, 2018, after market close. "This partnership with Nasdaq is a natural transition for Sanofi as it provides greater cost-efficiencies as well as access to a broad-based portfolio of investor relations tools to enhance both market insights and our interaction with the financial community," said Jean-Baptiste Chasseloup de Chatillon, Executive Vice President, Chief Financial Officer, Sanofi.
BOSTON, Dec. 18, 2018 /PRNewswire/ -- Santander Bank today announced that it has named Seth Goodall as Executive Director, Corporate Social Responsibility. In this role, Goodall is responsible for overseeing Santander's activities related to the Community Reinvestment Act ("CRA") and general corporate stewardship for the communities where Santander operates.
BOSTON, Dec. 3, 2018 /PRNewswire/ -- Santander Bank today announced that it has named David Harnisch Head of Commercial Banking. Harnisch joined Santander in 2017 as the Head of Underwriting, Portfolio Management and Commercial Strategy, and will now be responsible for leading and growing its commercial banking division.
BOSTON, Nov. 5, 2018 /PRNewswire/ -- Santander Bank today announced the opening of its first branch in the Flushing neighborhood of Queens, located on 136-11 Roosevelt Avenue. To commemorate the event, Santander leaders will join community partners at a grand opening celebration and ribbon cutting later today to officially open the branch. Santander will present checks totaling $52,000 to three community organizations – Renaissance Economic Development Corporation (REDC), Chinese American Planning and Flushing Development Center.